Skip to main content
. 2022 Sep 30;102(12):pzac129. doi: 10.1093/ptj/pzac129

Table 3.

Comparison of Percentages of Time Spent Frozen in Responders and Nonresponders While On and Off Dopaminergic Medicationsa

Parameter Variable Median (25%–75% Percentiles) for: P
Participants With Good Improvement While On Medication (>5%) (n = 14) Participants With Less or No Improvement While On Medication (<5%) (n = 14)
Participant characteristics and disease severity Age, y 70.00 (65.25–73.00) 71.00 (63.50–75.00) .93
Sex, % women 14.3 42.9 .94
Disease duration, y 14.00 (9.50–18.00) 9.50 (6.13–17.00) .44
MDS-UPDRS part III while off medicationb 50.50 (35.25–53.00) 45.00 (35.00–50.25) .34
MDS-UPDRS part III while on medicationb 37.00 (29.25–44.75) 32.50 (24.75–38.00) .48
MDS-UPDRS III, item 3.11 FOG, while off medicationb 2.00 (0.00–3.25) 2.00 (0.00–2.00) .28
MDS-UPDRS III, item 3.11 FOG, while on medicationb 1.00 (0.00–2.00) 1.50 (0.00–2.00 .55
Hoehn and Yahr stage 2.00 (1.50–2.13) 2.00 (1.88–2.00) .55
Gait speed during 4-m walk, m/s 1.15 (1.00–1.23) 0.94 (0.85–1.14) .04
LEDD, mg/d 832.50 (668.75–1653.75) 630.00 (311.25–1012.50) .03
Unsupervised home monitoring %TF during monitoring 2.8 (0.9–3.1) 0.6 (0.5–1.2) .01
No. of FOG episodes 876.00 (420.50–1491.25) 456.50 (265.75–525.50) .01
No. of FOG episodes/h 35.43 (14.93–43.64) 11.94 (8.76–22.09) .02
Daily usage of home monitoring device, min 221.90 (167.42–338.50) 223.55 (191.12–366.79) .41
Amount of FOG during supervised FOG-provoking tests (%TF) while off medication 4-m walk while off medicationc 2.4 (0.0–20.6) 0.0 (0.0–0.0) .03
TUG, single task, while off medicationc 2.7 (0.0–20.8) 0.0 (0.0–6.7) .20
TUG, dual task, while off medicationc 3.86 (0.0–41.9) 0.0 (0.0–4.4) .07
Turning task, single task, while off medicationc 42.7 (17.9–66.0) 9.1 (3.3–47.4) .05
Turning task, dual task, while off medicationc 43.2 (19.3–83.6) 8.4 (0.0–48.2) .03
Hot spot, narrow space, while off medicationc 8.8 (0.0–32.7) 0.9 (0.0–21.5) .38
Personal hot spot while off medicationc 31.0 (12.3–44.6) 4.8 (0.0–15.2) ≤.001d
Total %TF during provoking protocol while off medicationc 39.5 (17.4–47.6) 8.8 (3.5–30.8) .01
No. of FOG episodes/h while off medication 259.00 (142.97–320.13) 154.94 (66.01–180.96) .01
Amount of FOG during supervised FOG-provoking tests (%TF) while on medication 4-m walk while on medicationc 0.0 (0.0–0.0) 0.0 (0.0–0.0) .32
TUG, single task, while on medicationc 0.0 (0.0–0.0) 0.0 (0.0–1.5) .31
TUG, dual task, while on medicationc 0.0 (0.0–0.0) 0.0 (0.0–0.0) .78
Turning task, single task, while on medicationc 0.0 (0.0–39.8) 8.9 (0.0–57.8) .56
Turning task, dual task, while on medicationc 0.0 (0.0–50.3) 9.6 (0.0–47.6) .64
Hot spot, narrow space, while on medicationc 0.0 (0.0–0.0) 0.0 (0.0–1.5) .41
Personal hot spot while on medicationc 0.0 (0.0–6.9) 0.0 (0.0–4.7) .80
Total %TF during provoking protocol while on medicationc 3.1 (0.0–3.1) 6.2 (0.0–38.4) .38
No. of FOG episodes/h while on medication 66.53 (0.00–203.78) 173.20 (0.00–242.40) .59
Self-report questionnaires New Freezing of Gait Questionnaireb 23.50 (20.75–26.00) 20.00 (18.50–24.00) .04
Characterizing Freezing of Gait Questionnaireb 27.00 (19.50–37.75) 22.50 (15.75–33.25) .39
a

Unadjusted P values are shown. FOG = freezing of gait; LEDD = levodopa equivalent daily dose; MDS-UPDRS = Movement Disorders Society Unified Parkinson’s Disease Rating Scale; %TF = percentage of time spent frozen; TUG = Timed “Up & Go” Test.

b

Reported as a score.

c

Reported as percentage of time spent frozen.

d

Statistically significant after adjustment for multiple comparisons.